Media coverage about Chiasma (NASDAQ:CHMA) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chiasma earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.1064984801717 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Chiasma (NASDAQ CHMA) opened at $1.55 on Friday. The firm has a market capitalization of $36.57, a price-to-earnings ratio of -1.32 and a beta of 1.20. Chiasma has a twelve month low of $1.25 and a twelve month high of $2.95.
Chiasma (NASDAQ:CHMA) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.28) earnings per share for the quarter.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.